Sarepta said it accepts the CHMP decision on Elevidys, while partner Roche said it will continue working with the EMA.

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.